Mechanism of Action
Mechanism of Action for WELIREG®▼ (belzutifan)
Prescribing Information [External Link]
WELIREG is the first-and-only licensed selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α) and may reduce the transcription of certain target genes that drive tumour growth in VHL disease.1,2
Summary of the mechanism of action of WELIREG
As a selective HIF-2α inhibitor, WELIREG is the only licensed systemic treatment option for adult VHL patients with RCC, CNS Hb, or pNET, and for whom localised procedures are unsuitable or undesirable.1,2
Learn more about WELIREG & VHL disease:
Stay up to date with the latest on WELIREG
Receive data updates, resources and invites to meetings and events
Abbreviations
VHL = von Hippel-Lindau; HIF-1β = hypoxia-inducible factor 1 beta; RCC = renal cell carcinoma; CNS Hb = central nervous system hemangioblastomas; pNET = pancreatic neuroendocrine tumours.
References
- WELIREG Summary of Product Characteristics.
- Narayan V, Jonasch E. Systemic therapy development in von Hippel-Lindau disease: an outsized contribution from an orphan disease. Cancers (Basel). 2022;14(21):5313.
Indication
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
